Abstract miRNAs have shown promise as potential biomarkers for acute myocardial infarction (AMI). However, the current used quantitative real-time PCR (qRT-PCR) allows solely for relative expression of nucleic acids and it is susceptible to day-to-day variability, which has limited the validity of using the miRNAs as biomarkers. In this study we explored the technical qualities and diagnostic potential of a new technique, chip-based digital PCR, in quantifying the miRNAs in patients with AMI and ischaemia-reperfusion injury (I/R). In a dilution series of synthetic C elegans vs vs ST-elevation myocardial infarction (STEMI) and 20 patients with stable coronary artery disease (CAD) patients after percutaneous coronary intervention (PCI), we used qRT-PCR and multiplexed chip-based digital PCR to quantify the serum levels of miRNA-21 and miRNA-499 as they have been validated in AMI in prior studies. In STEMI, I/R injury was assessed via measurement of ST-segment vs P vs P vs P vs P<0.0001). There was no association between miR-21/499 levels and ST-R post-PCI. Our results show that the chip-based digital PCR exhibits superior technical qualities and promises to be a superior method for quantifying miRNA levels in the circulation, which may become a more accurate and reproducible method for directly quantifying miRNAs, particularly for use in large multi-centre clinical trials.
Introduction micro-RNAs (miRNAs) are small non-coding RNAs (~22 nucleotide-long) involved in the post-transcriptional regulation of genetic expression via alteration of messenger RNA translation [1] . miRNAs are known to be released into the circulation in both physiological and pathological states [1] . Given their proposed physiological roles, as well as their remarkable stability in the circulation, miRNAs have become attractive candidates as novel biomarkers [2] . In recent years, a variety of miRNAs have demonstrated potential as possible biomarkers for myocardial damage [2] [3] [4] . Of particular interest for this study are miRNA-21 and miRNA-499. miRNA-21 is known to have a plethora of functions in health and disease, specifically involved in both enhancing the function of stem and progenitor cells in AMI and contributing to post-AMI fibrogenesis and cellular hypertrophy [5] [6] [7] . miRNA-499 is found in myocardial and skeletal muscle, and has been physiologically linked to cardiac differentiation and I/R injury [8] [9] [10] . Both miRNAs have been validated as upregulated in AMI, and miRNA-499 has even shown potential as a biomarker in I/R injury [11] [12] [13] [14] [15] [16] . Despite showing promise, a number of issues have arisen which have limited the validity of using these and other miRNAs as biomarkers [17] . Foremost amongst these limitations is the current method for quantifying miRNAs, quantitative real-time PCR (qRT-PCR) [18] . qRT-PCR allows solely for relative expression of nucleic acids and it is susceptible to day-to-day variability, limiting its ability to be used as a diagnostic medium or in validating miRNAs in large multi-centre clinical trials [18] . Digital PCR is an end-point analysis, which is able to absolutely quantify nucleic acids directly within a sample by partitioning a sample into mutliple smaller reactions, whereby each division may or may not contain a nucleic acid [19] . Current methods to allow for this include multi-well plates, capillaries, oil emulsions and arrays of miniaturised chambers [19] . Digital PCR has thus far exhibited a number of unique advantages over qRT-PCR, including decreased variability, increased day-today reproducibility and superior sensitivity [20] [21] [22] . It can be proposed that with these advantages, digital PCR would offer greater comparability and hence greater utility as a diagnostic machine and in large multi-centre clinical trials.
At current, there are a number of comercially available digital PCR systems, each utilising a different method to achieve absolute quantification. QuantStudio ® 3D digital PCR is a relatively novel method of digital PCR, which loads a PCR sample onto a microchip, partitioning the sample across 20 000 reaction wells, essentially allowing 20 000 separate PCR reactions to take place [23] . The QuantStudio ® system uses a Poisnegative wells to allow for absolute quantification, without need for referencing to a standard control [23] . A small number of studies have demonstrated its promising use as a robust tool for quantitative analysis of nucleic acids for a wide range of biomedical applications [22] [23] [24] [25] . At current there is little evidence with regard to the technical precision of this system, and to the best of our knowledge, none examining its use in diagnosing AMI with validated miRNAs. This project aims to address the current limitations of using miRNAs as valid biomarkers for AMI and reperfusion injury, and to explore the role of chip-based digital PCR in quantifying these miRNAs.
Materials and methods

Synthetic oligonucleotide dilution series of C.elegans-miR-39
A dried 5'-phosphorylated synthetic oligonucleotide for Caenorrhabditis elegans-miR-39 (C.elegans-miR-39) (Integrated DNA Technologies) (5'-phos-UCACCGGGUGUAAAU-CAGCUUG-3'), with a known starting concentration of 7.6 nmol was centrifuged dry before being diluted in molecular grade Tris-EDTA buffer (Thermo Fisher Scientific) to performed for C.elegans-miR- 39 /well 20× specific hydrolysis primer/probe were combined before being partitioned into 9.5 /well with 5 /well RT product. Thereafter, 14.5 of each sample were loaded onto a chip and transferred to the ProFlex TM 2× Flat PCR System (ThermoFisher) and underwent thermal cycling set for 14.5 at 96°C for 10 min, 60°C for 2 min, 98°C for 30 s, with the cycling being repeated for 39 more cycles, with a final extension at 60°C for 2 more minutes and then held at 10 °C. Chips were then read by the QuantStudio TM 3D Digital PCR Instrument (ThermoFisher).
The technical qualities of chip-based digital PCR versus qRT-PCR were compared statistically by a number of methods.
The coefficient of variation was calculated by the following equation:
The CV% was calculated for each dilution of the oligonucleotide for chip-based digital PCR. Values with no-call . Before calculating the CV% for each diluent in qRT-PCR, the Ct values were converted to absolute copies using the Pfaffl analysis [26] :
Where E target
The control for the Pfaffl equation was calculated by calculating the mean of the highest concentration (i.e.
), and comparing that to each sample. Each sample could then be converted to absolute copies by the following equation:
Absolute copies= R×2500
The qRT-PCR data could then be analysed for CV% and compared with the absolute quantification determined by chip-based digital PCR. Reduction in CV% for each diluent across each day was calculated by the equation:
testing [27] , removing successive diluton points until the P-value was >0.05 (Prism Version 5.0c software). The limit of detec- Percutaneous coronary intervention PCI was performed with standard catheters. All STEMI patients received aspirin (minimum of 250 mg) and an ADP receptor blocker (prasugrel 60 mg, ticagrelor 180 mg or clopidogrel 600 mg). Unfractionated heparin (5000 U) was administered prior to angiography. Eptifibatide was given at the discretion of the cardiologist.
miRNA extraction
Before undergoing miRNA extraction, all serum samples were 5 
C.elegans-miR-39
to act as an endogenous control. Serum samples underwent miRNA extraction according to the manufacturer's instructions (Qiagen).
Reverse transcription, qRT-PCR and Quantstudio ® 3D Digital PCR Samples underwent reverse transcription, qRT-PCR and chip-based digital PCR according to the above-mentioned protocols. Every sample also underwent separate RT and qRT-PCR and chip-based digital PCR for C.elegansmiR-39 to act as an endogenous control. Chip-based digital PCR was performed multiplexed by using a mastermix well Quantstudio ® 3D supermix (ThermoFisher), 0.725 primer set for either hsa-miR-21-5p or hsa-miR-499-5p hydrolysis probe and primer set for C.elegans-miR-39 VIC labelled (ThermoFisher; ID: 000200). We then normalised the data across samples using a median normalisation procedure (normalisation factor = median value of all C.elegans-miR-39 measurements/C.elegans-miR-39 value for the given sample) [26] .
Ischaemia-reperfusion injury
ECGs were analysed within the STEMI group both before and 2.25 h (1.5-3.5) after PCI. In keeping with prior studies, we used Schröder's criteria and defined ST-segment resolu- [29] [30] [31] . Patients who fulfilled suffered significant I/R injury. Four of the STEMI patients had to be excluded from analysis, due to a lack of required ECGs in the hospital's database.
Statistical analysis
Continuous variables are presented as mean±standard deviation (SD) if found to follow a Gaussian distribution according to a D'Agostino-Pearson omnibus normality test, or as median and interquartile range if found to follow a nonGaussian distritbution. Normally distributed variables were compared using the Student's t-test and non-normally distributed variables using the Mann-Whitney U test. Categorical variables are presented as percentages. A Chi-square analysis was performed to compare categorical variables. A receiver operating characteristic (ROC) analyis was per--sis being the area under the curve (AUC).
miR-21/499 levels between STEMI patients deemed to have suffered I/R injury compared to those who reached adequate reperfusion were compared using a Mann-Whitney U test, and ROC analyses were performed for each miRNA.
Analyses for correlations between clinical characteristics and miR-21 and miR-499 levels were performed by Pearson analysis for parametric data or a Spearman test for non-parametric data.
A P for all analyses except for the analysis of correlation. This particular analysis involved multiple comparisons, thus requiring correction via Bonferroni's method. This set the new statisti-P-value at 0.0029 for the correlation analysis.
All analyses were performed using Graph Pad Prism v5.0
Results
Dilution series of synthetic C.elegans-miR-39
Chip-based digital PCR demonstrated a lower coefficient of variation between most dilution points ( Figure 1A Figure 1B) . Finally, chip-based digital PCR demonstrated a superior Through absolute quantification, we noted measurements by chip-based digital PCR corresponding to 57.6% of the expected copy number.
Patient characteristics
The patient population consisted of 73% men and the aver- Chip-based digital PCR for the diagnosis of ischaemia-reperfusion injury Neither chip-based digital PCR nor qRT-PCR were able to -els between patients deemed to be successfully reperfused and those who suffered I/R injury (Figure 4) . A ROC analysis demonstrated that miR-499 was most accurately able to differ- Figure S1 ). Figure S2 .
Correlation analysis
Discussion -lutely quantify nucleic acids within a biological sample [19] . Given its reputed advantages over traditional qRT-PCR, digital PCR could be a superior method for the detection of miRNAs for both diagnostic purposes and in validating miRNA expressions in large multi-centre studies. The recently developed Quantstudio ® 3D digital PCR is one of a number of digital in order to partition a sample into 20 000 reaction wells, [23] . Other currently available systems favour an oil-emulsion droplet generation few studies investigating the use of chip-based digital PCR system in quantifying miRNAs, and, to the best of our knowledge, none that have investigated its utility for diagnosing AMI or reperfusion injury with miRNAs. With this report, we of miRNAs using a combination of both synthetic oligonucleotides and validated human cardiovascular miRNAs extracted from patient serum for AMI and reperfusion injury. For patient samples we used a multiplexed PCR protocol combining the normalistion miRNA (C.elegans-miR-39) and the target miRNA.
in a dilution series of synthetic C.elegans-miR-39
In a dilution series of synthetic C.elegans-miR-39, chip-based digital PCR demonstrated lower variability, higher linearity and superior sensitivity compared to qRT-PCR. Through absolute quantification, we observed that the copy numbers actually detected were lower than the numbers that were expected. This has been demonstrated in a number of other papers examining absolute quantification as a method for PCR, and is most likely due to suboptimal reverse transcription [21, 23] . Ultimately, chip-based digital PCR demonstrated superior technical characteristics indicating that it could miRNAs.
patients compared to patients with stable CAD Both miR-21 and miR-499 were found to be significantly dysregulated in STEMI patients compared to patients with stable CAD as quantified by chip-based digital PCR. miR-21 levels were found to decrease in STEMI patients by both PCR systems. This is in contrast to other studies, which have shown that miR-21 levels increase in the circulation as a result of infarction [11, 12] . This might be explained by the difference between the times blood was taken in past studies compared to this study. Past studies have analysed blood at the time of admission, whereas this study analysed blood 5±SD 2.7 h after PCI 11, 12] . It is therefore possible that miR-21 levels could decrease below normal levels according to its kinetics, or decrease as a result of therapeutic success. According to a et al revealed that long-term elevation in miR-21 levels is deleterious to post-infarct repair, contributing to left-ventricular [34] . Given the above information and the knowledge that miRNAs have endocrinelike roles, it is feasible that miR-21 levels are released during the acute phase of AMI, possibly via the rupture of necrotic/ apoptotic cardiomyocytes, while after successful reperfusion, and the offset of cardiomyocyte death, miR-21 might repair, hence leading to a decrease in serum levels. However, patients and potentially animal experimentation. miR-499 levels, on the other hand, were found to increase in STEMI patients, which is consistent with the current literature [12, 14, 16] . In past studies, miR-499 has shown as much as 80 to 3×10 5 -fold differences between AMI and control groups [12, 16] . In this study, qRT-PCR and chip-based digital PCR only demonstrated approximately 21 and 4-fold difference between mean values respectively. The reason for this may once again be due to the time blood was drawn, this being post-PCI, whereas the aforementioned studies analysed blood at admission. In Chen's study of miR-499 kinetics, there was a 58% decrease in miR-499 levels 24-h post-PCI and 48% lower levels in those who received PCI compared to those who did not [14] . Therefore, the lower levels found in our study may be due to therapeutic reperfusion and might also be a marker of therapeutic success. This evidence also gives credence to the hypothesis that miR-21 levels decrease after PCI indicating therapeutic intervention.
from stable CAD patients for miRNA-21, but not for miRNA-499 For miRNA-21, chip-based digital PCR, unlike qRT-PCR, and exhibited superior sensitivity and specificity as demonstrated by ROC analysis, giving clinically relevant evidence to its diagnostic potential. Conversely, for miR-499, qRT-PCR reached superior significance. This discrepency might be explained by the fact that miR-499 is normally expressed at levels below the limit of detection of qRT-PCR [13, 14] . This was verified in our experiments, whereby qRT-PCR only detected miR-499 in 45% of patients with stable CAD and 83% of STEMI patients, whereas chip-based digital PCR was able to quantify levels in 100% of the patients analysed, even at low concentrations. Our experiments on synthetic C.elegansmiR-39 also agreed with past studies that demonstrated superior sensitivity for detecting miRNAs using digital PCR [21, 35] . Therefore, this system might be a better reflection of actual miRNA-499 levels, and might be better able to quantify both this miRNA and others that are normally expressed at minimal levels within the circulation. However, this needs to be validated in larger studies. Ultimately, chip-based digital PCR exhibited promising potential for quantifying miRNA-21 and miRNA-499 levels for analysis in cardiovascular biology. We demonstrated that Quantstudio ® 3D digital PCR is a robust system with clinical diagnostic potential and technical qualities for use in large multi-centre miRNA studies.
Chip-based digital PCR did not demonstrate increases of miRNA-21 or miRNA-499 in ischaemia-reperfusion injury In our study, neither miRNA-21 nor miRNA-499 demonstrated 499 as measured by chip-based digital PCR showed the greatest trend, which is in keeping with past studies that suggested a role of miRNA-499 in cardiac I/R injury [10] . A study with a larger patient cohort utilising other markers of reperfusion injury is required.
necrosis markers
In a correlation analysis miR-499 demonstrated a significant positive correlation with both peak CK and CK-MB levels as measured by chip-based digital PCR. Both CK and CK-MB AMI [36] [37] [38] [39] . This indicates that miR-499 possibly has similar utility. miR-499 presents itself as a particularly interesting biomarker for AMI. miR-499 is normally expressed at low levels, and has high myocardial specificity [13, 14] . Furthermore, past studies have demonstrated significant increases in miR-499 reperfusion [12] [13] [14] 16] . We therefore propose that miR-499 might -tic marker. However, further studies are needed looking at the infarct in order to validate this hypothesis. It must also be mentioned that there was a positive correlation between miR-499 and eptifibatide use. This is most likely explainable by the fact that only patients with STEMI received eptifibatide, population. Furthermore, in a subgroup analysis, those who received eptifibatide had significantly higher miR-499 levels, and eptifibatide use was positively correlated with miRthe treating cardiologist. As per the 2017 European Society of Cardiology guidelines for STEMI, GP IIb/IIIa inhibitors such as eptifibatide should be reserved for bailout if there is evithrombotic complications [40] . Consequently, it can be argued that miR-499 levels were higher in more complicated STEMI cases, giving further evidence to miR-499's validity as a clinically interesting biomarker for AMI.
Limitations
Despite demonstrating promising technical qualities and has a number of limitations. In the synthetic dilution series we detected absolute copy numbers lower than the copy numbers expected, possibly suggesting suboptimal assay design and/or reverse transcription. Furthermore, the patient cohort was relatively small and there was no healthy control group. miRNA-499 failed to reach significance in association with reperfusion injury. Furthermore, only one surrogate marker of reperfusion injury was assessed, this being ECG post PCI. Other markers such as cardiac MRI must be integrated into future studies. Moreover, a true association between miRNAdirectly assessed, as these parameters were not analysed. Finally, we only compared qRT-PCR to one method of digital PCR, this being the Quantstudio ® 3D system. This was suffurther studies comparing a variety of digital PCR methods -and further investigation into the physiology of miRNA-21 and miRNA-499 must be undertaken.
In conclusion, we have demonstrated that chip-based digital PCR has a number of promising characteristics allowing its potential use as a more accurate method for validating miRNA levels, particularly in large multi-centre clinical trials. Chipbased digital PCR exhibited low variability, high linearity and remarkable sensitivity and showed promise as a diagnostic instrument. These results warrant further investigation and validation in larger more comprehensive studies. Neverthe-
